Page last updated: 2024-11-02

pioglitazone and Centriacinar Emphysema

pioglitazone has been researched along with Centriacinar Emphysema in 1 studies

Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.

Research Excerpts

ExcerptRelevanceReference
"Pioglitazone-pretreated ASCs had a more potent therapeutic effect than non-pretreated ASCs in the repair of both elastase-induced and smoke-induced emphysema models (mean linear intercept, 78."1.43Therapeutic effects of adipose-derived stem cells pretreated with pioglitazone in an emphysema mouse model. ( Hong, SH; Hong, Y; Kim, YS; Oh, YM, 2016)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Hong, Y1
Kim, YS1
Hong, SH1
Oh, YM1

Other Studies

1 other study available for pioglitazone and Centriacinar Emphysema

ArticleYear
Therapeutic effects of adipose-derived stem cells pretreated with pioglitazone in an emphysema mouse model.
    Experimental & molecular medicine, 2016, 10-21, Volume: 48, Issue:10

    Topics: Adipose Tissue; Animals; Cell Line; Disease Models, Animal; Female; Lung; Mice, Inbred C57BL; Pancre

2016